netscientific
  • ABOUT US
  • TEAM
    • CAREERS
  • PORTFOLIO
  • INVESTORS
    • RNS & RNS REACH
    • FINANCIAL RESULTS
    • CORPORATE GOVERNANCE
  • NEWS
    • RESEARCH REPORTS
  • 2022 AGM NOTICE
  • CONTACT US
netscientific
netscientific
  • ABOUT US
  • TEAM
    • CAREERS
  • PORTFOLIO
  • INVESTORS
    • RNS & RNS REACH
    • FINANCIAL RESULTS
    • CORPORATE GOVERNANCE
  • NEWS
    • RESEARCH REPORTS
  • 2022 AGM NOTICE
  • CONTACT US

Announcement of research agreement with Harvard

May 19, 2014
-
News, RNS Announcements
RNS Number : 3950H
NetScientific PLC
19 May 2014

 

NetScientific announces research agreement with Harvard University

 

 

NetScientific plc (AIM:NSCI, ‘NetScientific’ or ‘The Group’), the biomedical and healthcare technology investment group, is pleased to announce that Vortex, its Palo Alto based spinout, has signed an agreement with the Rowland Institute at Harvard University.  Under the research agreement, the Rowland Institute will explore the use of circulating tumor cell (CTC) technology in a study to analyze improvements in patient diagnosis and prognosis that may be possible from capturing live CTCs in blood samples. If successful, the company believes that, once the processes are fully developed, they could transform the way medical practitioners select drug treatments for patients and how new classes of anticancer therapeutics are developed.

Vortex’s technology enables direct selection and capture of live CTCs from whole blood.  Cells can be captured and held within the Vortex microfluidic chip for enumeration and analysis and work at the Rowland Institute will focus on effecting and evaluating potential drug treatment of live CTCs within the Vortex chip.

 

 

For further information, please contact:

 

  Liberum (Nomad & Broker)

  Chris Bowman / Christopher Britton / Thomas Bective

Tel: 020 3100 2000

  Bell Pottinger

  Daniel de Belder

Tel: 020 7861 3232

 

Company website:www.netscientific.net

 

 

ABOUT NETSCIENTIFIC

NetScientific is a healthcare and life sciences company with global reach that funds and develops technologies that offer transformative benefits to peoples’ lives and society through improved diagnosis, prognosis and treatment. The group is primarily focused on identifying and developing cutting edge technologies with applications in several: (i) cardiovascular; (ii) liver; (iii) cancer; (iv) metabolic; and (v) digital health.

 

ABOUT VORTEX

Vortex Biosciences, Inc.(Vortex) is developing a novel liquid biopsy technology that could revolutionise cancer diagnosis and monitoring.

 

Based in Palo Alto, California, and formed in 2010, Vortex has exclusive, world-wide rights to all technologies developed in connection with a project from a laboratory based at a leading University in the USA.

 

NetScientific’s cancer diagnostics company is developing blood test cancer diagnostics by detecting, quantifying and harvesting Circulating Tumor Cells.  These live CTCs offer important possibilities in advanced therapeutics and personalised medicine. 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange

END

MSCLLFSEEEIRLIS

Share on FacebookShare on TwitterShare on Linkedin
← PREVIOUS POST
Result of AGM
NEXT POST →
Posting of Annual Report and Notice of AGM

 

NetScientific plc

Level 39,
One Canada Square,
London, E14 5AB

Tel: +44 20 3514 1800
www.netscientific.net
info@netscientific.net

  • RNS & RNS Reach
  • Financial Results
  • Financial Calendar
  • Corporate Governance
  • News
  • Historic Material
Copyright
Terms of Use
Announcement of research agreement with Harvard - NetScientific
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT